Lipid Metabolism Disorders
Conditions
Keywords
prevention of cardiovascular diseases, atorvastatin
Brief summary
A systematic collection of retrospective and prospective data based on non-interventional patient observation, aimed to assess the risks, course and outcomes of a disease or a group of diseases: * the retrospective part: database of patients with cardiovascular risks; * the prospective part: observation of patients in the real world medical practice.
Detailed description
The research program will have two parts: Stage 1: identification of patients with moderate, high and very high cardiovascular risk, not having diseases of atherosclerotic genesis and requiring lipid-lowering drugs. Stage 2: a prospective observation of patients receiving primary medical prophylaxis of CVD with atorvastatin.
Interventions
DRUGatorvastatin
Profound patients' consultations (different from standard practice) on the importance of primary prevention of cardiovascular diseases, including preventive administration of statins. Subjects in profound consultation group will receive regular reminders (2 times a month) via SMS and phone calls to check following the doctor's recommendations and remind about follow-up visit to study centre.
Sponsors
National Research Center for Preventive Medicine
The League of Clinical Research, Russia
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
40 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Data on the following subjects is planned to be collected in the project: * Aged from 40 to 65 years inclusively * With a high (≥5%) cardiovascular risk measured by SCORE and low density lipoprotein (LDL) levels of ≥2,5 mmol/L, or with a very high (≥10%) cardiovascular risk measured by SCORE and LDL levels ≥1,8 mmol/L or With atherosclerotic stenosis of brachiocephalic arteries of \>50% in the absence of cerebrovascular disease
Exclusion criteria
* No contraindications to statin treatment and not taking stating at study entry. * History of the following clinically significant events and conditions: (а) myocardial infarction (б) stroke (в) transient ischemic attack * Presence of the following diseases at the time of a statin administration: (а) ischemic heart disease (б) heart failure (в) peripheral artery atherosclerosis (г) atherosclerotic stenosis of brachiocephalic arteries with cerebrovascular disease . Subjects must give their consent for processing of their personal data for the purposes of this scientific project.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Target level of LDL cholesterol | 12 months | To assess number of patients achieving the target level of low-density lipoprotein cholesterol in study group and in control group. |
Countries
Russia
Outcome results
None listed